Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung Cancer (aNSCLC) is osimertinib, followed by cytotoxic chemotherapy. The repeat of osimertinib following previous treatment failure is investigational, although supported by scientific rationale. The dosing and scheduling of osimertini

Trial Details

NCT ID
NCT04335292
Phase
PHASE2
Sponsor
Mark Vincent
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Osimertinib First-Line
  • Platinum + Pemetrexed Chemotherapy Second-Line
  • Osimertinib Third-Line
Locations (sample)
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Brampton, Ontario, Canada|43.68341,-79.76633
  • Hamilton, Ontario, Canada|43.25011,-79.84963
  • Kitchener, Ontario, Canada|43.42537,-80.5112

Key Eligibility Criteria

  • Provision of informed consent prior to any study specific procedures
  • Male or female patients of at least 18 years of age
  • Pathologically proven advanced non-small cell lung cancer (i.e. stage M1 (metastasis), or earlier stages if unfit or unsuitable for radical treatme…
  • Patients must have a known activating Epidermal Growth Factor Receptor (EGFR) mutation. Atypical Epidermal Growth Factor Receptor (EGRF) mutations …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →